5/15/2025

Janusmed sex and gender

Janusmed sex and gender – Heparin

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C C
C C

Heparin

Heparin

Class : C

Show all info

Print

Contact us

  1. Campbell NR, Hull RD, Brant R, Hogan DB, Pineo GF, Raskob GE. Different effects of heparin in males and females. Clin Invest Med. 1998;21:71-8.

  2. Granger CB, Hirsch J, Califf RM, Col J, White HD, Betriu A et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation. 1996;93:870-8.

  3. Toss H, Wallentin L, Siegbahn A. Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease. Am Heart J. 1999;137:72-8.

  4. Lansky AJ, Mehran R, Cristea E, Parise H, Feit F, Ohman EM et al. Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial). Am J Cardiol. 2009;103:1196-203.

  5. Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, Allen-LaPointe NM et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005;294:3108-16.

  6. HEPARIN SODIUM injection (heparin sodium). DailyMed [www]. US National Library of Medicine. [updated 2018-08-01, cited 2019-02-19].

  7. Asgar A, Chandrasekhar J, Mikhail G, Webb J, Lefèvre T, Tamburino C et al. Sex-based differences in outcomes with bivalirudin or unfractionated heparin for transcatheter aortic valve replacement: Results from the BRAVO-3 randomized trial. Catheter Cardiovasc Interv. 2017;89(1):144-153.

  8. Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood. 2006;108:2937-41.

  9. Falvo N, Bonithon-Kopp C, Rivron Guillot K, Todoli JA, Jiménez-Gil M, Di Micco P et al. Heparin-associated thrombocytopenia in 24,401 patients with venous thromboembolism: findings from the RIETE Registry. J Thromb Haemost. 2011;9:1761-8.

  10. Alsayegh F, Al-Rasheed M, Al-Muhaini A, Al-Humoud E, Al-Ostaz M, Mousa SA. Heparin anticoagulation responsiveness in a coronary care unit: a prospective observational study. Cardiovasc Ther. 2009;27:77-82.

  11. Concise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2019-03-14.]

  1. Campbell NR, Hull RD, Brant R, Hogan DB, Pineo GF, Raskob GE. Different effects of heparin in males and females. Clin Invest Med. 1998;21:71-8.
  2. Granger CB, Hirsch J, Califf RM, Col J, White HD, Betriu A et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation. 1996;93:870-8.
  3. Toss H, Wallentin L, Siegbahn A. Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease. Am Heart J. 1999;137:72-8.
  4. Lansky AJ, Mehran R, Cristea E, Parise H, Feit F, Ohman EM et al. Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial). Am J Cardiol. 2009;103:1196-203.
  5. Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, Allen-LaPointe NM et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005;294:3108-16.
  6. HEPARIN SODIUM injection (heparin sodium). DailyMed [www]. US National Library of Medicine. [updated 2018-08-01, cited 2019-02-19].
  7. Asgar A, Chandrasekhar J, Mikhail G, Webb J, Lefèvre T, Tamburino C et al. Sex-based differences in outcomes with bivalirudin or unfractionated heparin for transcatheter aortic valve replacement: Results from the BRAVO-3 randomized trial. Catheter Cardiovasc Interv. 2017;89(1):144-153.
  8. Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood. 2006;108:2937-41.
  9. Falvo N, Bonithon-Kopp C, Rivron Guillot K, Todoli JA, Jiménez-Gil M, Di Micco P et al. Heparin-associated thrombocytopenia in 24,401 patients with venous thromboembolism: findings from the RIETE Registry. J Thromb Haemost. 2011;9:1761-8.
  10. Alsayegh F, Al-Rasheed M, Al-Muhaini A, Al-Humoud E, Al-Ostaz M, Mousa SA. Heparin anticoagulation responsiveness in a coronary care unit: a prospective observational study. Cardiovasc Ther. 2009;27:77-82.
  11. Concise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2019-03-14.]